Abstract
A humanized version of the apoptosis-inducing mouse anti-human Fas monoclonal antibody, HFE7A, is under further development for the treatment of autoimmune diseases such as rheumatoid arthritis. We have crystallized the antigen-binding fragment (Fab) of the humanized HFE7A. The crystals belong to the orthorhombic space group P2 1 2 1 2 1 with cell dimensions a = 54.4 Å, b = 82.7 Å, c = 104.9 Å and contain one Fab molecule in the asymmetric unit. X-ray diffraction data were collected to 2.8 Å resolution.
Keywords: fab fragment, humanized hfe7a, fas monoclonal antibody
Protein & Peptide Letters
Title: Crystallization and Preliminary X-Ray Studies of the Fab Fragment from a Humanized Version of the Mouse Anti-Human Fas Antibody Hfe7a
Volume: 9 Issue: 3
Author(s): Shuichiro Ito, Tomoko Takayama, Hiroyuki Hanzawa, Tohru Takahashi, Kenji Miyadai, Nobufusa Serizawa, Hideyuki Haruyama and Tadashi Hata
Affiliation:
Keywords: fab fragment, humanized hfe7a, fas monoclonal antibody
Abstract: A humanized version of the apoptosis-inducing mouse anti-human Fas monoclonal antibody, HFE7A, is under further development for the treatment of autoimmune diseases such as rheumatoid arthritis. We have crystallized the antigen-binding fragment (Fab) of the humanized HFE7A. The crystals belong to the orthorhombic space group P2 1 2 1 2 1 with cell dimensions a = 54.4 Å, b = 82.7 Å, c = 104.9 Å and contain one Fab molecule in the asymmetric unit. X-ray diffraction data were collected to 2.8 Å resolution.
Export Options
About this article
Cite this article as:
Ito Shuichiro, Takayama Tomoko, Hanzawa Hiroyuki, Takahashi Tohru, Miyadai Kenji, Serizawa Nobufusa, Haruyama Hideyuki and Hata Tadashi, Crystallization and Preliminary X-Ray Studies of the Fab Fragment from a Humanized Version of the Mouse Anti-Human Fas Antibody Hfe7a, Protein & Peptide Letters 2002; 9 (3) . https://dx.doi.org/10.2174/0929866023408715
DOI https://dx.doi.org/10.2174/0929866023408715 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
T Lymphocytes as Targets of Statins: Molecular Mechanisms and Therapeutic Perspectives
Inflammation & Allergy - Drug Targets (Discontinued) A Review of Natural and Synthetic Antioxidants Important for Health and Longevity
Current Medicinal Chemistry A QSAR Study on a Series of Pyrrole Derivatives Acting as Lymphocyte- Specific Kinase (Lck) Inhibitors
Medicinal Chemistry State of the Art on Carbonic Anhydrase Modulators for Biomedical Purposes
Current Medicinal Chemistry Enzyme Inhibition as a Key Target for the Development of Novel Metal-Based Anti-Cancer Therapeutics
Anti-Cancer Agents in Medicinal Chemistry Gene and Cancer Therapy - Pseudorabies Virus: A Novel Research and Therapeutic Tool?
Current Gene Therapy P2X7 Receptors: Channels, Pores and More
CNS & Neurological Disorders - Drug Targets Transglutaminase-Catalyzed Reactions Responsible for the Pathogenesis ofCeliac Disease and Neurodegenerative Diseases: From Basic Biochemistry to Clinic
Current Medicinal Chemistry Albumin-Based Nanodevices as Drug Carriers
Current Pharmaceutical Design Pre-B Cell Colony Enhancing Factor/NAMPT/Visfatin in Inflammation and Obesity- Related Disorders
Current Pharmaceutical Design On the Structural Plasticity of the Human Genome: Chromosomal Inversions Revisited
Current Genomics Advances in the Development of Class I Phosphoinositide 3-Kinase (PI3K) Inhibitors
Current Topics in Medicinal Chemistry Viruses and Multiple Sclerosis
CNS & Neurological Disorders - Drug Targets Design of a Peptide Inhibitor of Tyrosine Kinase 2
Protein & Peptide Letters Proteins of the Esterase Family: Patents for Some Proteins in Search of Metabolic Functions
Recent Patents on Biomarkers Metformin one in a Million Efficient Medicines for Rheumatoid Arthritis Complications: Inflammation, Osteoblastogenesis, Cardiovascular Disease, Malignancies
Current Rheumatology Reviews Mitochondria-Mediated Oxidative Stress: Old Target for New Drugs
Current Medicinal Chemistry The Role of Integrin-Mediated Cell Adhesion in Atherosclerosis: Pathophysiology and Clinical Opportunities
Current Pharmaceutical Design Ethosomes and its Applications in Transdermal Drug Delivery
Current Drug Therapy Circulating MicroRNAs as Biomarkers for Inflammatory Diseases
MicroRNA